The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Gene therapy for pain: Results of a phase I clinical trial
Open accessAbstract
Objective: Preclinical evidence indicates that gene transfer to the dorsal root ganglion using replication‐defective herpes simplex virus (HSV)‐based vectors can reduce pain‐related behavior in animal models of pain. This clinical trial was carried out to assess the safety and explore the potential efficacy of this approach in humans. Methods: We conducted a multicenter, dose‐escalation, phase I clinical trial of NP2, a replication‐defective HSV‐based vector expressing human preproenkephalin ( PENK ) in subjects with intractable focal pain caused by cancer. NP2 was injected intradermally into the dermatome(s) corresponding to the radicular distribution of pain. The primary outcome was safety. As secondary measures, efficacy of pain relief was assessed using a numeric rating scale (NRS), the Short Form McGill Pain Questionnaire (SF‐MPQ), and concurrent opiate usage. Results: Ten subjects with moderate to severe intractable pain despite treatment with >200mg/day of morphine (or equivalent) were enrolled into the study. Treatment was well tolerated with no study agent‐related serious adverse events observed at any point in the study. Subjects receiving the low dose of NP2 reported no substantive change in pain. Subjects in the middle‐ and high‐dose cohorts reported pain relief as assessed by NRS and SF‐MPQ. Interpretation: Treatment of intractable pain with NP2 was well tolerated. There were no placebo controls in this relatively small study, but the dose‐responsive analgesic effects suggest that NP2 may be effective in reducing pain and warrants further clinical investigation. ANN NEUROL 2011
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central sensitization: implications for the diagnosis and treatment of pain
Woolf, C. J. (2011) · Pain · doi:10.1016/j.pain.2010.09.030 · Cited by 4,771
Opioids in chronic non-cancer pain: systematic review of efficacy and safety
Kalso, E., Edwards, J. E., Moore, A. R., & McQuay, H. J. (2004) · Pain · doi:10.1016/j.pain.2004.09.019 · Cited by 1,216
Cited by
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Soft, stretchable, fully implantable miniaturized optoelectronic systems for wireless optogenetics
Park, S. I., Brenner, D. S., Shin, G., Morgan, C. D., Copits, B. A., Chung, H. U., Pullen, M. Y., Noh, K. N., Davidson, S., Oh, S. J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3415 · Cited by 794
The NaV1.7 sodium channel: from molecule to man
Dib-Hajj, S. D., Yang, Y., Black, J. A., & Waxman, S. G. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3404 · Cited by 613
Neurological perspectives on voltage-gated sodium channels
Eijkelkamp, N., Linley, J. E., Baker, M. D., Minett, M. S., Cregg, R., Werdehausen, R., Rugiero, F., & Wood, J. N. (2012) · Brain · doi:10.1093/brain/aws225 · Cited by 359
Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain
Berta, T., Qadri, Y., Tan, P.-H., & Ji, R.-R. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1328057 · Cited by 257
Metadata
- Authors
- Fink, D. J., Wechuck, J., Mata, M., Glorioso, J. C., Goss, J., Krisky, D., & Wolfe, D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-07-27
- Volume
- 70
- Issue
- 2
- Pages
- 207-212
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2004321823
- Cited by
- 172
- References
- 2
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy for pain: Results of a phase I clinical trial. https://app.cochat.ai/papers/10.1002/ana.22446
- The paper
- Fink, D. J., Wechuck, J., Mata, M., Glorioso, J. C., Goss, J., Krisky, D., & Wolfe, D. (2011). Gene therapy for pain: Results of a phase I clinical trial. Annals of Neurology. https://doi.org/10.1002/ana.22446
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.